Talal Hilal, MB, BCh, assistant professor of Medicine at Mayo Clinic, discusses the benefit of maintenance rituximab (Rituxan) in the treatment of patients with mantle cell lymphoma (MCL).
Talal Hilal, MB, BCh
Advertisement
Articles by Talal Hilal, MB, BCh
Talal Hilal, MB, BCh, assistant professor of medicine, Mayo Clinic, discusses a study of rituximab (Rituxan) maintenance in patients with mantle cell lymphoma (MCL) after induction chemoimmunotherapy.
Talal Hilal, MB, BCh, assistant professor of medicine, Mayo Clinic, discusses the meta-analysis of rituximab maintenance for patients with mantle cell lymphoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
Olverembatinib Plus Blinatumomab Yields High Early-Phase CR/CRi Rates in R/R Ph+ CML and B-ALL
4
Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL
5